Prevalence, targeted treatment and prevention of eye disorders in diabetes

Predictive Diagnostics and Personalized Treatment: Dream or Reality

Volumn , Issue , 2009, Pages 231-246

  Josifova, Tatjana ^a   Henrich, Paul B ^a   Schrader, Wolfgang ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Maximilians Hospital Nürnberg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892293700     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (62)

1. Guyer DR, Yannuzzi LA, Chang S, Shields JA, Green WR (1999) Retina-Vitreous-macula. Saunders publisher.
2. Peppa M, Urribari J, Vlassara H (2003) Glucose, advanced glycation end products, and diabetes complications: What is new and what works. Clin. Diabetes, 21, 186-187.
3. Trautner C (2008) Epidemiologie des diabetes mellitus. www.medizin-aktuell.de/cm-diabetes/.
4. Grammas P, Riden M (2003) Retinal endothelial cells are more susceptible to oxidative stress and increased permeability than brain-derived endothelial cells. Microvasc. Res., 65, 18-23.
5. American Academy of Ophthalmology (2002) http://www.aao.org
6. Lewis H, Ryan RJ (1994) Medical and Surgical Retina Advances, Controversies and Management. Mosby: St Louis, 257-321.
7. Kent D, Vinores SA, Campochiaro PA (2000) Macular oedema: the role of soluble mediators. Br. J. Ophthalmol., 84, 542-545.
8. Blum M, Kloos C, Muller N, Mandecka A, Berner R, Bertram B, Müller UA (2007) [Prevalence of diabetic retinopathy. Check-up program of a public health insurance company in Germany 2002-2004]. Ophthalmologe, 104, 499-504.
9. Hein TW, Yuan Z, Rosa RH Jr, Kuo L (2005) Requisite roles of A2A receptors, nitric oxide, and KATP channels in retinal arterioral dilatation in response to adenosine. Invest. Ophthalmol. Vis. Sci., 46, 2113-2119.
10. Ravid M, Savin H, Lang R, Jutrin I, Shoshana L, Lishner M (1992) Proteinuria, renal impairment, metabolic control, and blood pressure in type 2 diabetes mellitus. A 14 years follow-up report on 195 patients. Arch. Intern. Med., 152, 1225-1229.
11. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metmorfin on complications in overweight patients with type 2 diabetes. Lancet, 352, 854-856.
12. Aiello LM (2003) Perspectives on diabetic retinopathy. Am. J. Ophthalmol., 136, 122-135.
13. Arjamaa O, Nikinmaa M (2006) Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp. Eye Res., 83, 473-483.
14. Chase HP, Garg SK, Harris S, Hoops S, Jackson WE, Holmes DL (1993) Angiontesin converting enzyme inhibitor treatment for young normotensive diabetic subjects, a two year trail. Ann. Ophthalmol., 25, 284-289.
15. Funatsu H, Yamashita H, Nakanishi Y, Hori S (2002) Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br. J. Ophthalmol., 86, 311-315.
16. Hogeboom van Buggenum IM, Polak BC, Reichert-Thoen JW, Vries-Knoppert WA, van Hinsbergh VW, Tangelder GJ (2002) Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with lower vitrous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Diabetologia, 45, 203-209.
17. Priglinger SG, Krentzer TC (2008) Therapiestrategien bei diabetischer Retinopathie. www.Pharmazeutische-zeitung.de
18. Stur M, Egger S, Haas A, Kiselbach G, Mennel S, Michl R, Wedrich A, Roden M (2004) [Diagnosis, therapy and follow-up of diabetic eye diseases]. Acta. Medica Austriaca, 31, 179-181.
19. Beckendorf A, Kusserow C, Schmidt-Erfurth U (2001) Proteinkinase C (PKC) and vascular endothelial growth factor (VEGF) inhibition in diabetic maculopathy. Ophthalmologe, 98, S5.
20. Clermont A, Tagaki C, Jirousek M, Bursell S, King G (1995) A PKC b isoform selective antagonist normalised retinal blood flow in STZ diabetic rats: first report of an oral agent selective for the PKC b isoenzyme. Invest. Ophthalmol. Vis. Sci., 36, S173.
21. Tesfamariam B, Brown ML, Cohen RA (1991) Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J. Clin. Invest., 87, 1643-1648.
22. Greene DA, Lattimer SA, Sima AA (1987) Sorbitol, phosphoinositides, and sodium-potassium-ATP-ase in the pathogenesis of diabetic complications. N. Engl. J. Med., 316, 599-606.
23. Orgül S (2000) Pharmacotherapy in Glaucoma, Hans Huber publisher.
24. Meyer P, Lang MG, Flammer J, Lüscher T (1995) Effects of calcium channel blockers on the response to endothelin-1, bradykinin and sodium nitroprusside in porcine ciliary arteries. Exp. Eye Res., 60, 505-510.
25. Early Treatment Diabetic Retinopathy Study Research Group (1987) Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report No.2. Ophthalmology, 94, 761-774.
26. Dorner GT, Garhofer G, Huemer KH, Riva CE, Schmetterer L (2003) Hyperglicemia affects flicker-induced vasodilatation in the retina of healthy subjects. Vision Res., 43, 1495-1500.
27. Grunwald JE, Riva CE, Brucker AJ, Sinclair SH, Petrig BL (1986) Effect of panretinal photocoagulation on retinal blood flow in proliferative diabetic retinopathy. Ophthalmology, 93, 590-595.
28. Stefansson E, Machemer R, de Juan E Jr, McCuen BW 2nd, Peterson J (1992) Retinal oxygenation and laser treatment in patients with diabetic retinopathy. Am. J. Ophthalmol., 113, 36-38.
29. The Diabetic Retinopathy Study Research Group (1979) Four risk factors for severe visual loss in diabetic retinopathy: the third report from Diabetic Retinopathy Study. Arch. Ophthalmol., 97, 654-655.
30. The Diabetic Retinopathy study Research Group (1987) Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study report No 14. Int. Ophthalmol. Clin., 27, 239-253.
31. Meyer CH (2007) Current treatment approaches in diabetic macular edema. Ophthal-mologica, 221, 118-131.
32. Early Treatment Diabetic Retinopathy Study Research Group (1991) Early photocoagulation for diabetic retinopathy. ETDRS report No 9. Ophthalmology, 98, 766-785.
33. Fong DS, Ferris FL, Davis MD, Chew EY (1999) Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report No. 24. Early Treatment Diabetic Retinopathy Study Research Group. Am. J. Ophthalmol., 127, 137-141.
34. Keech AC, Mitchell P, Summannen PA, O'Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen LT, d'Emden MC, Crimet DC, O'Connell RL, Colman PG; FIELD study investigators (2007) Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial. Lancet, 370, 1687-1697.
35. Sebag J, Buckingham B, Charles MA, Reiser K (1992) Biochemical abnormalities of vitreous in humans with proliferative diabetic retinopathy. Arch. Ophthalmol., 110, 1472-1476.
36. Yamamoto T, Akabane N, Takeuchi S (2001) Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimaculare membrane. Am. J. Ophthalmol., 132, 369-377.
37. Sebag J, Nie S, Reiser K, Charles MA, Yu NT (1994) Raman spectroscopy of human vitreous in proliferative diabetic retinopathy. Invest. Ophthalmol. Vis. Sci., 35, 2976-2980.
38. Sebag J, Balazs EA (1984) Pathogenesis of cystoid macular edema: an anatomic consideration of vitreoretinal adhesion. Surv. Ophthalmol., 28, 493-498.
39. Gandorfer A, Messmer EM, Ulbig MW, Kampik A (2000) Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina, 20, 126-133.
40. Micelli Ferrari T, Cardascia N, Durante G, Vetrugno M, Cardia L (1999) Pars plana vitrectomy in diabetic macular edema. Doc. Ophthalmol., 97, 471-474.
41. Kumagai K, Ogino N, Furukawa M, Demizu S, Atsumi K, Kurihara H, Iwaki M, Ishigooka H, Tachi N (2002) [Internal limiting membrane peeling in vitreous surgery for diabetic macular edema]. Nippon Ganka Gakkai Zasshi, 106, 590-594.
42. Kuhn F, Kiss G, Mester V, Szijarto Z, Kovacs B (2004) Vitrectomy with internal limiting membrane removal for clinically significant edema. Graefes Arch. Clin. Exp. Ophthalmol., 242, 402-408.
43. La Heij EC, Hendrikse F, Kessels AG, Derhaag PJ (2001) Vitrectomy results in diabetic macular edema without evident vitreomacular traction. Graefes Arch. Clinic. Exp. Ophthalmol., 239, 264-270.
44. Lewis H, Abrams GW, Blumenkranz MS, Campo RV (1992) Vitrectomy for diabetic macular traction and edema associated with posterior traction. Ophthalmology, 99, 753-759.
45. Lewis H (2001) The role of vitrectomy in the treatment of diabetic macular edema. Am. J. Ophthalmol., 131, 123-125.
46. Haefliger I, Meyer P, Flammer J, Lüscher T (1994) The vascular endothelium as a regulator of the ocular circulation: a new concept in ophthalmology? Surv. Ophthalmol., 39, 123-132.
47. Dorner GT, Garhofer G, Kiss B, Polska E, Polak K, Riva CE, Schmetterer L (2003) Nitric oxide regulates retinal vasculare tone in humans. Am. J. Physiol. Heart Circ. Physiol., 285, H631-H636.
48. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, Yeo KT (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol., 118, 445-450.
49. Adamis AP, Shima DT, Yeo KT, Yeo TK, Brown LF, Berse B, D'Amore PA, Folkman J (1993) Synthesis and secretion of vascular permeability factor, vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem. Biophys. Res. Commun., 193, 631-638.
50. Stiris T, Suguihara C, Hehre D, Goldberg RN, Flynn J, Bancalari E (1992) Effect of cyclooxygenase inhibition on retinal and choroidal blood flow during hypercapnia in newborn piglets. Pediatr. Res., 31, 127-130.
51. Watanabe D, Suzuma K, Suzuma I, Ohashi H, Ojima T, Kurimoto M, Murakami T, Kimura T, Takagi H (2005) Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am. J. Ophthalmol., 139, 476-481.
52. Itakura H, Kishi S, Kotajima N, Murakami M (2004) Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy. Ophthalmology, 111, 1880-1884.
53. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C (2002) Intravitreal triamcinolone for refractory diabtic macular edema. Ophthalmology, 109, 920-927.
54. Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan E Jr. (1992) Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal coagulation. Arc. Ophthalmol., 110, 1155-1159.
55. Cellini M, Pazzaglia A, Zamparini E, Leonetti P. Campos EC (2008) Intravitreal vs. subtenon triamcinolone acetonide for the treatment of diabetic cystoid macular edema. BMC Ophthalmol., 8, 5.
56. Jonas JB, Kreissig I, Sofker A, Degenring RF (2003) Intravitreal injection of triamcinolone for diffuse diabtic macular edema. Arch. Ophthalmol., 121, 57-61.
57. Jonas JB, Kreissig I, Degenring R (2003) Secondary chronic open-angle glaucoma after intravitreal triamcinolone acetonide. Arch. Ophthalmol., 121, 729-730.
58. Jonas JB (2004) Intravitreales Triamcinolonacetonoid (editorial). Ophthalmologe, 101, 111-112.
59. Charters L (2008) Intravitreal drugs promising to treat diabetic retinopathy, but dosing still suboptimal. http://ophthalmologytimes.modernmedicine.com/
60. Mosfhegi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP, Kaiser RS, Bakri SJ, Maturi RK, Belmont J, Beer PM, Murray TG, Quiroz-Mercado H, Mieler WF (2003) Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am. J. Ophthalmol., 136, 791-796.
61. Jaissle GB, Szurman P, Bartz-Schimdt KU, German Retina Society; German Society of Ophthalmology; German Professional Association of Ophthalmologists (2005) [Recommendation for the implementation of intravitreal injections - statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA)]. Klin Monatsbl Augenheilkd, 222, 390-395.
62. Michels S, Agostini H (2007) Inhibition der Angiogenese in der Augenheilkunde: (Eds), UNI-MED publisher.